Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.

Add item related to this paper

  • MiniManuscript ID
    162048
  • Pubmed ID
    19716456